Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Investors are dropping dollars into the life sciences industry like the trees are dropping their leaves. Here’s who’s raking in the cash this week.
Cue Health went public on September 24 on the Nasdaq securities exchange under the ticker symbol HLTH.
Population demographics appear to play a crucial role in the development of immunity via vaccination.
Takeda entered into a licensing pact with Poseida, Spark entered into a licensing agreement with CombiGene AB, while BridgeBio Pharma announced plans for its second annual R&D Day.
GSK shares are climbing in premarket trading on rumors that the company’s consumer health business it intends to spin off into a separate company next year is attracting interest from venture capitalists.
The positive results from a mechanistic study of TTP399 in type 1 diabetes patients suggest that the drug can lower blood glucose without increasing the risk of DKA.
Teamed up with pharma giant GlaxoSmithKline, CureVac is now focusing on a more promising target – second-generation mRNA vaccines.
Two months after J&J CEO Alex Gorsky announced plans to step down, Chief Scientific Officer Paul Stoffels will retire from the life sciences giant at the end of the year.
Although there are many effective and safe COVID-19 vaccines around the world, the preferred vaccine is the Pfizer-BioNTech vaccine. For that and more stories, read on.
Evidence is emerging that not only can COVID-19 vaccines help to prevent the condition, but they could serve as a form of “rescue” for those already stricken with it.
The NIH revealed that bumetanide, a drug typically used as a diuretic, maybe a potential treatment for those genetically at risk for Alzheimer’s. Know more about it here.
This followed a report that found that some trustees had, perhaps, taken advantage of this close connection with startups and research programs for their financial gain.